Differential effects of cancer modifying agents during radiation therapy on Ehrlich solid tumor-bearing mice: A comparative investigation of metformin and ascorbic acid

• Published in: Applied radiation and isotopes 2022-09, Vol.187, p.110305-110305, Article 110305
• Main Authors: Ali, Mennat-Allah, Khalil, Magdy M., Al-Mokaddem, Asmaa K., Aljuaydi, Samira H., Ahmed, M.M., Khalil, Heba M.A.
• Format: Article
• Language: English
• Subjects: Anti-Cancer; Ascorbic; Metformin; Radiation therapy; Tumor inhibition
• ISSN: 0969-8043; 1872-9800
• DOI: 10.1016/j.apradiso.2022.110305

This work was carried out to compare the modifying roles of ascorbic and metformin during Ehrlich (ESC) tumor-bearing mice irradiation. Fifty Swiss albino male mice were segmented into seven groups, including one control group and six Ehrlich induced tumors treated with ascorbic, ascorbic plus radiation, metformin, metformin plus radiation, and radiation only. Many tests, including behavioral, biochemical, immunohistochemistry, gene expression, DNA fragmentation, oxidative stress markers, and EPR, were performed to interrogate the modifying effects on tumor and liver tissues. Remarkable apoptosis was found in metformin irradiated animals compared to irradiated ascorbic counterparts. The irradiated metformin mice showed the greatest reduction in PCNA. There was a significant reduction of DNA fragmentation in the liver tissues of the irradiated metformin group. Irradiated metformin and irradiated ascorbic acid animals showed a reduced signal of ERK as well as c-Fos genes. There was a tendency of metformin and metformin irradiated animals to reduce MDA levels in liver tissues. ESC-bearing mice treated with ascorbic or metformin showed an improvement in the spontaneous alternation percentage (SAP%) and improved short-term memory. There was also an improvement in long memory tests. The study added more preclinical evidence on the utility of metformin in cancer treatment during radiotherapy. Metformin was shown to reduce lipid peroxidation in irradiated healthy tissues, increase tumor cytotoxicity, downregulate critical pathways involved in tumor progression and proliferation, and enhance tumor apoptosis. Controlled clinical trials using metformin are highly warranted. •The study added more preclinical evidence on the utility of metformin in cancer treatment.•Metformin was shown to reduce lipid peroxidation in irradiated healthy tissues, increase tumor cytotoxicity.•Metformin have multiple cellular targets and need further investigation for prope utilization .•A controlled clinical trials using metformin are highly warranted.